Patents by Inventor Dipak Raychand Lagad

Dipak Raychand Lagad has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors
    Patent number: 11952380
    Abstract: The invention relates to substituted bicyclic heterocyclic compounds of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.
    Type: Grant
    Filed: May 6, 2022
    Date of Patent: April 9, 2024
    Assignee: LUPIN LIMITED
    Inventors: Prathap Sreedharan Nair, Ganesh Bhausaheb Gudade, Sachin Sethi, Dipak Raychand Lagad, Chetan Sanjay Pawar, Mahadeo Bhaskar Tryambake, Chaitanya Prabhakar Kulkarni, Anil Kashiram Hajare, Balasaheb Arjun Gore, Sanjeev Anant Kulkarni, Milind Dattatraya Sindkhedkar, Venkata P. Palle, Rajender Kumar Kamboj
  • PRMT5 INHIBITORS
    Publication number: 20220315589
    Abstract: The invention relates to substituted nucleoside analogues of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.
    Type: Application
    Filed: June 9, 2020
    Publication date: October 6, 2022
    Inventors: Prathap Sreedharan Nair, Ganesh Bhausaheb Gudade, Mahadeo Bhaskar Tryambake, Chetan Sanjay Pawar, Dipak Raychand Lagad, Chaitanya Prabhakar Kulkarni, Milind Dattatraya Sindkhedkar, Venkata P. Palle, Rajender Kumar Kamboj
  • Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors
    Patent number: 11459330
    Abstract: The invention relates to substituted bicyclic heterocyclic compounds of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: October 4, 2022
    Assignee: LUPIN LIMITED
    Inventors: Prathap Sreedharan Nair, Ganesh Bhausaheb Gudade, Sachin Sethi, Dipak Raychand Lagad, Chetan Sanjay Pawar, Mahadeo Bhaskar Tryambake, Chaitanya Prabhakar Kulkarni, Anil Kashiram Hajare, Balasaheb Arjun Gore, Sanjeev Anant Kulkarni, Milind Dattatraya Sindkhedkar, Venkata P. Palle, Rajender Kumar Kamboj
  • SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS
    Publication number: 20220267339
    Abstract: The invention relates to substituted bicyclic heterocyclic compounds of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.
    Type: Application
    Filed: May 6, 2022
    Publication date: August 25, 2022
    Applicant: LUPIN LIMITED
    Inventors: Prathap Sreedharan Nair, Ganesh Bhausaheb Gudade, Sachin Sethi, Dipak Raychand Lagad, Chetan Sanjay Pawar, Mahadeo Bhaskar Tryambake, Chaitanya Prabhakar Kulkarni, Anil Kashiram Hajare, Balasaheb Arjun Gore, Sanjeev Anant Kulkarni, Milind Dattatraya Sindkhedkar, Venkata P. Palle, Rajender Kumar Kamboj
  • SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS
    Publication number: 20210163486
    Abstract: The invention relates to substituted bicyclic heterocyclic compounds of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions for treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme. The invention also relates to methods of treating diseases, disorders or conditions associated with the overexpression of PRMT5 enzyme.
    Type: Application
    Filed: December 13, 2018
    Publication date: June 3, 2021
    Applicant: LUPIN LIMITED
    Inventors: Prathap Sreedharan Nair, Ganesh Bhausaheb Gudade, Sachin Sethi, Dipak Raychand Lagad, Chetan Sanjay Pawar, Mahadeo Bhaskar Tryambake, Chaitanya Prabhakar Kulkarni, Anil Kashiram Hajare, Balasaheb Arjun Gore, Sanjeev Anant Kulkarni, Milind Dattatraya Sindkhedkar, Venkata P. Palle, Rajender Kumar Kamboj
  • Quinolizinone derivatives as PI3K inhibitors
    Patent number: 9944639
    Abstract: Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R1-R4, and n are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PI3K enzyme of a subject.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: April 17, 2018
    Assignee: Lupin Limited
    Inventors: Manojkumar Ramprasad Shukla, Nirmal Kumar Jana, Sachin Jaysing Mahangare, Prashant Popatrao Vidhate, Dipak Raychand Lagad, Anand Jagannath Tarage, Sanjeev Anant Kulkarni, Venkata P. Palle, Rajender Kumar Kamboj
  • QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS
    Publication number: 20170137421
    Abstract: Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R1-R4, and n are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PI3K enzyme of a subject.
    Type: Application
    Filed: July 1, 2015
    Publication date: May 18, 2017
    Applicant: Lupin Limited
    Inventors: Manojkumar Ramprasad Shukla, Nirmal Kumar Jana, Sachin Jaysing Mahangare, Prashant Popatrao Vidhate, Dipak Raychand Lagad, Anand Jagannath Tarage, Sanjeev Anant Kulkarni, Venkata P. Palle, Rajender Kumar Kamboj